A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol.
Saved in:
| Title: | A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol. |
|---|---|
| Authors: | García-García I; Clinical Pharmacology Department, University Hospital La Paz, Madrid, Spain., Guerra-García P; Clinical Pharmacology Department, University Hospital La Paz, Madrid, Spain.; Pediatric Hemato-oncology Department, University Hospital La Paz, Madrid, Spain.; Hospital La Paz Institute for Health Research, IdiPAZ, University Hospital La Paz, Madrid, Spain., Ferreras C; Hospital La Paz Institute for Health Research, IdiPAZ, University Hospital La Paz, Madrid, Spain., Borobia AM; Clinical Pharmacology Department, University Hospital La Paz, Madrid, Spain.; Hospital La Paz Institute for Health Research, IdiPAZ, University Hospital La Paz, Madrid, Spain.; Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain., Carcas AJ; Clinical Pharmacology Department, University Hospital La Paz, Madrid, Spain.; Hospital La Paz Institute for Health Research, IdiPAZ, University Hospital La Paz, Madrid, Spain.; Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain., Queiruga-Parada J; Clinical Pharmacology Department, University Hospital La Paz, Madrid, Spain., Vicario JL; Regional Blood Transfusion Centre, Madrid, Spain., Mirones I; Pediatric Hemato-oncology Department, University Hospital La Paz, Madrid, Spain., Solano C; Hospital Clínico Universitario de Valencia/Instituto de Investigación Sanitaria INCLIVA, Universidad de Valencia, Valencia, Spain., Eguizabal C; Research Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Bizkaia, Spain.; Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Bizkaia, Spain., Soria B; Institute of Bioengineering, Miguel Hernández University, Elche, Alicante, Spain.; Health Research Institute-ISABIAL, Alicante University Hospital, Alicante, Spain.; University Pablo de Olavide, Sevilla, Spain., Pérez-Martínez A; Pediatric Hemato-oncology Department, University Hospital La Paz, Madrid, Spain. aperezmartinez@salud.madrid.org.; Hospital La Paz Institute for Health Research, IdiPAZ, University Hospital La Paz, Madrid, Spain. aperezmartinez@salud.madrid.org.; Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain. aperezmartinez@salud.madrid.org. |
| Source: | Trials [Trials] 2021 Oct 02; Vol. 22 (1), pp. 674. Date of Electronic Publication: 2021 Oct 02. |
| Publication Type: | Clinical Trial Protocol; Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215 (Electronic) Linking ISSN: 17456215 NLM ISO Abbreviation: Trials Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1745-6215 |
|---|---|
| DOI: | 10.1186/s13063-021-05625-7 |
